SRT501
Neoplasms, Colorectal
Sirtris, a GSK CompanyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
118 Active assets in the Neoplasms, Colorectal cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Peking University Cancer Hospital & Institute | Phase 4 | BBB |
FLUOROURACILUM Rutgers, The State University of New Jersey | Phase 4 | BBB |
Capecitabine Rutgers, The State University of New Jersey | Phase 4 | BBB |
Ferric Carboxymaltose [Ferinject] Nottingham University Hospitals NHS Trust | Phase 4 | BBB |
Irinotecan Shanghai Zhongshan Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
SRT501 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →